ClinicalTrials.gg
CompletedNCT02071225Updated Feb 7, 2020Results posted

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

A Phase 2 interventional study of bendamustine and obinutuzumab in Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Completed at 21 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-07.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 3 under way, 1 of them phase 3. bendamustine · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
13th of 46
72 · median 35
Started
2014
with 3 others
Phase 2
22 of 46
1 open now
Registered
33rd of 46
by date
Lead sponsor
2 of 46
Hoffmann-La Roche

Among the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 22 in phase 2, and was the 33rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing bendamustine in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase II trial was designed to evaluate the efficacy of obinutuzumab and bendamustine treatment in participants with refractory or relapsed chronic lymphocytic leukemia (CLL). Participants receive up to six 28-day cycles of treatment. Treatment consists of intravenous (IV) administration of obinutuzumab and bendamustine. Treatment time is expected to last 6 months, and participant follow-up will last 2 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosed CD20+ B- chronic lymphocytic leukemia (CLL) according to National Cancer Institute (NCI) criteria
  • Active disease meeting at least 1 of the International Workshop on CLL (IWCLL) 2008 criteria for treatment
  • CLL (i.e. treatment failure or progression during treatment or within 6 months after the last treatment) or relapse CLL (i.e. participants who met criteria for CR or PR, but progressed beyond 6 months post-treatment)
  • At least 1 prior purine analogue or bendamustine containing therapy
  • greater than (>) 6 months
  • Use of effective as described in the study protocol

Exclusion criteria

Exclusion Criteria:

  • Prior Alogenic Bone Marrow Transplant
  • Greater than or equal to (>/=) 3 and/or immunotherapy for the CLL
  • Previous obinutuzumab-containing regimen
  • Treatment failure or progression within 6 months of bendamustine-containing regimen
  • Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL; Richter's transformation) Patients with prolymphocytic transformation cannot entry the study either
  • Active haemolytic anaemia
  • Inadequate liver function
  • History of other which could affect compliance with the protocol or interpretation of results. Patients with a history of malignancy that has been treated but not with curative intent will be excluded, unless the malignancy has been in remission without treatment for >/= 2 years prior to enrolment. Patients with a history of adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent are eligible
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
  • Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
  • Regular treatment with during the 4 weeks prior to study start, unless administered for another condition at a dose equivalent to less than or equal to (\</=) 30 milligrams per day (mg/day) prednisone
  • Known active infection or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to study start
  • Patients with , human T cell leukemia virus 1 (HTLV-1), or
  • Pregnancy or breast-feeding
  • Vaccination with a within 4 weeks prior to baseline visit
  • Receipt of any other study drug within 4 weeks prior to study start
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Obinutuzmab + Bendamustine

    Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles

    Drug: bendamustine · Drug: obinutuzumab

Interventions

  • 70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.

  • 1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.

    Also known as: RO5072759

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria

    ORR was defined as percentage of participants achieving Complete Response (CR), incomplete CR (CRi) or Partial Response (PR). CR: lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, hepatomegaly and splenomegaly, absence of disease or constitutional symptoms, neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L, bone marrow at least normocellular for age. CRi: CR with persistent cytopenia, i.e. anemia, thrombocytopenia and/or neutropenia. PR: reduction ≥ 50% of the lymphocyte count AND reduction ≥ 50% of the lymphadenopathy OR reduction ≥ 50% of the size of the liver if enlarged at baseline OR reduction ≥ 50% of the size of the spleen if enlarged at baseline PLUS one of the following: neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L or increase ≥ 50% compared to pre-treatment.

    Time frame: 2-3 months after last dose of the study treatment (up to approximately 9 months)

Secondary outcomes

  1. Best Response Rate as Assessed by the Investigator Using the IWCLL 2008 Criteria

    Best overall response was defined as percentage of participants achieving a best response of CR, CRi and PR. CR: lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, hepatomegaly and splenomegaly, absence of disease or constitutional symptoms, neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L, bone marrow at least normocellular for age. CRi: CR with persistent cytopenia, i.e. anemia, thrombocytopenia and/or neutropenia. PR: reduction ≥ 50% of the lymphocyte count AND reduction ≥ 50% of the lymphadenopathy OR reduction ≥ 50% of the size of the liver if enlarged at baseline OR reduction ≥ 50% of the size of the spleen if enlarged at baseline PLUS one of the following: neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L or increase ≥ 50% compared to pre-treatment.

    Time frame: During study treatment and until 6 months after end of study treatment at approximately 12 months

  2. Progression Free Survival (PFS)

    PFS is defined as the time from the start of treatment to disease progression (DP), relapse or death from any cause, whichever occurs first, as assessed by the investigator. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal chronic lymphocytic leukemia (CLL) cells.

    Time frame: From start of treatment up to disease progression or relapse or death, whichever occurred first (up to approximately 4.5 years)

  3. Overall Survival (OS)

    OS was defined as the time from the start of study treatment to death from any cause.

    Time frame: From start of treatment up to death of any cause (up to approximately 4.5 years)

  4. Event Free Survival (EFS)

    EFS was defined as the time from the start of treatment to DP/relapse, death from any cause or start of a new anti-leukemia therapy. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

    Time frame: From start of treatment up to disease progression or relapse or death or start of a new anti-leukemic therapy, whichever occurred first (up to approximately 4.5 years)

  5. Disease Free Survival (DFS)

    DFS was defined for all participants who achieved complete response (CRi or CR). DFS lasted from the date on which CRi or CR was recorded until the date on which the first DP or death from any cause occurred. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

    Time frame: From occurrence of complete response up to disease progression or death, whichever occurred first (up to approximately 4.5 years)

  6. Duration of Response (DR)

    DR was defined for participants with CRi, CR or PR. DR spanned from the date on which response was recorded until the date on which DP or death from any cause occurred. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

    Time frame: From occurrence of CR or PR up to disease progression or death, whichever occurred first (up to approximately 4.5 years)

  7. Time to Re-treatment/New Anti-leukemia Therapy

    Time to re-treatment/new leukemia therapy was defined as the time between the start of treatment and the date of the first administration of re-treatment or new leukemia therapy.

    Time frame: Up to 4.5 years

  8. Percentage of Participants With Minimal Residual Disease (MRD) Negativity

    MRD negativity was defined as the presence of less than 1 cell of CLL per 10,000 leukocytes (= category 0, \<0.01%) assessed in bone marrow (BM) and peripheral blood (PB) by flow cytometry after the end of the treatment at the final response assessment.

    Time frame: At approximately 9 months

  9. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE was any AE that was any of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, and was considered a significant medical event by the investigator.

    Time frame: Up to approximately 4.5 years

  10. Percentage of Participants With AEs of Special Interest (AESIs)

    AESIs included any of the following: SAEs associated with the infusion of obinutuzumab: obinutuzumab serious infusion-related reactions, which were defined as AEs occurring during or within 24 hours following the administration of an infusion of obinutuzumab and considered related to obinutuzumab; serious infection; serious neutropenia; any tumor lysis syndrome (TLS); second malignancies.

    Time frame: Up to approximately 4.5 years

  11. Percentage of Participants With Infusion-related Reactions (IRRs)

    IRRs were defined as AEs occurring during or within 24 hours following the administration of an infusion and considered related to drug treatment.

    Time frame: Up to end of treatment at 6 months

  12. Percentage of Participants Who Discontinued Treatment Prematurely

    Time frame: Up to end of treatment at 6 months

  13. Percentage of Participants With Previous/Concomitant Diseases

    Time frame: Up to approximately 4.5 years

  14. Percentage of Participants With Concomitant Medication

    Concomitant therapies included any medication (prescription medication, over-the-counter medications, herbal/homeopathic remedies, nutritional supplements) used by subjects in the 7 days prior to screening until the end of treatment. The following treatments were not permitted during the study treatment period: investigational or unauthorized or unapproved medicinal products, immunotherapy or radioimmunotherapy (other than the trial immunotherapy, obinutuzumab), chemotherapy (other than the trial chemotherapy, bendamustine) and radiotherapy.

    Time frame: From 7 days prior to screening to the end of treatment at 6 months

07

Results

Posted Nov 26, 2019

Participant flow

A total of 72 participants were recruited at 20 sites in Spain.

Participant flow — Overall Study
MilestoneObinutuzumab + Bendamustine
Started72
Completed42
Not completed30
Withdrew: Withdrawal of consent2
Withdrew: Protocol deviation1
Withdrew: Lost to follow-up2
Withdrew: Death25

Outcome measures

PrimaryOverall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria

ORR was defined as percentage of participants achieving Complete Response (CR), incomplete CR (CRi) or Partial Response (PR). CR: lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, hepatomegaly and splenomegaly, absence of disease or constitutional symptoms, neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L, bone marrow at least normocellular for age. CRi: CR with persistent cytopenia, i.e. anemia, thrombocytopenia and/or neutropenia. PR: reduction ≥ 50% of the lymphocyte count AND reduction ≥ 50% of the lymphadenopathy OR reduction ≥ 50% of the size of the liver if enlarged at baseline OR reduction ≥ 50% of the size of the spleen if enlarged at baseline PLUS one of the following: neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L or increase ≥ 50% compared to pre-treatment.

Time frame:
2-3 months after last dose of the study treatment (up to approximately 9 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria
percentage of participantsObinutuzumab + Bendamustine
Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria78.6 (66.8 to 87.1)
SecondaryBest Response Rate as Assessed by the Investigator Using the IWCLL 2008 Criteria

Best overall response was defined as percentage of participants achieving a best response of CR, CRi and PR. CR: lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, hepatomegaly and splenomegaly, absence of disease or constitutional symptoms, neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L, bone marrow at least normocellular for age. CRi: CR with persistent cytopenia, i.e. anemia, thrombocytopenia and/or neutropenia. PR: reduction ≥ 50% of the lymphocyte count AND reduction ≥ 50% of the lymphadenopathy OR reduction ≥ 50% of the size of the liver if enlarged at baseline OR reduction ≥ 50% of the size of the spleen if enlarged at baseline PLUS one of the following: neutrophils \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \> 110 g/L or increase ≥ 50% compared to pre-treatment.

Time frame:
During study treatment and until 6 months after end of study treatment at approximately 12 months
Reported as:
Number · percentage of participants
Best Response Rate as Assessed by the Investigator Using the IWCLL 2008 Criteria
percentage of participantsObinutuzumab + Bendamustine
CR46.3
CRi1.9
PR42.6
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the start of treatment to disease progression (DP), relapse or death from any cause, whichever occurs first, as assessed by the investigator. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal chronic lymphocytic leukemia (CLL) cells.

Time frame:
From start of treatment up to disease progression or relapse or death, whichever occurred first (up to approximately 4.5 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsObinutuzumab + Bendamustine
Progression Free Survival (PFS)24.14 (20.81 to 27.47)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of study treatment to death from any cause.

Time frame:
From start of treatment up to death of any cause (up to approximately 4.5 years)
Reported as:
Median · months
Overall Survival (OS)
monthsObinutuzumab + Bendamustine
Overall Survival (OS)NA (NA to NA)
SecondaryEvent Free Survival (EFS)

EFS was defined as the time from the start of treatment to DP/relapse, death from any cause or start of a new anti-leukemia therapy. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

Time frame:
From start of treatment up to disease progression or relapse or death or start of a new anti-leukemic therapy, whichever occurred first (up to approximately 4.5 years)
Reported as:
Median · months
Event Free Survival (EFS)
monthsObinutuzumab + Bendamustine
Event Free Survival (EFS)24.14 (19.96 to 28.32)
SecondaryDisease Free Survival (DFS)

DFS was defined for all participants who achieved complete response (CRi or CR). DFS lasted from the date on which CRi or CR was recorded until the date on which the first DP or death from any cause occurred. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

Time frame:
From occurrence of complete response up to disease progression or death, whichever occurred first (up to approximately 4.5 years)
Reported as:
Median · months
Disease Free Survival (DFS)
monthsObinutuzumab + Bendamustine
Disease Free Survival (DFS)23.02 (21.38 to 24.66)
SecondaryDuration of Response (DR)

DR was defined for participants with CRi, CR or PR. DR spanned from the date on which response was recorded until the date on which DP or death from any cause occurred. DP: at least one of the following characteristics: increase ≥ 50% in lymphocytes up to at least 5 x 10\^9/L, appearance of new palpable lymph nodes, increase ≥ 50% of the longest diameter of any previous area of clinically significant lymphadenopathy, increase ≥ 50% of the size of the liver and/or spleen, transformation to a more aggressive histology, after treatment, progression of any cytopenia: decrease of hemoglobin levels of more than 20 g/L or to below 100 g/L and/or decrease of platelet counts by more than 50% or to below 100 x 10\^9/L and/or decrease in the neutrophil counts by more than 50% or to below 1.0 x 10\^9/L if the marrow biopsy also shows infiltration of clonal CLL cells.

Time frame:
From occurrence of CR or PR up to disease progression or death, whichever occurred first (up to approximately 4.5 years)
Reported as:
Median · months
Duration of Response (DR)
monthsObinutuzumab + Bendamustine
Duration of Response (DR)21.41 (17.60 to 25.22)
SecondaryTime to Re-treatment/New Anti-leukemia Therapy

Time to re-treatment/new leukemia therapy was defined as the time between the start of treatment and the date of the first administration of re-treatment or new leukemia therapy.

Time frame:
Up to 4.5 years
Reported as:
Median · months
Time to Re-treatment/New Anti-leukemia Therapy
monthsObinutuzumab + Bendamustine
Time to Re-treatment/New Anti-leukemia TherapyNA (NA to NA)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD) Negativity

MRD negativity was defined as the presence of less than 1 cell of CLL per 10,000 leukocytes (= category 0, \<0.01%) assessed in bone marrow (BM) and peripheral blood (PB) by flow cytometry after the end of the treatment at the final response assessment.

Time frame:
At approximately 9 months
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) Negativity
percentage of participantsObinutuzumab + Bendamustine
MRD in BM: Cat 036.4
MRD in PB: Cat 053.4
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE was any AE that was any of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, and was considered a significant medical event by the investigator.

Time frame:
Up to approximately 4.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsObinutuzumab + Bendamustine
AEs94.4
SAEs51.4
SecondaryPercentage of Participants With AEs of Special Interest (AESIs)

AESIs included any of the following: SAEs associated with the infusion of obinutuzumab: obinutuzumab serious infusion-related reactions, which were defined as AEs occurring during or within 24 hours following the administration of an infusion of obinutuzumab and considered related to obinutuzumab; serious infection; serious neutropenia; any tumor lysis syndrome (TLS); second malignancies.

Time frame:
Up to approximately 4.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With AEs of Special Interest (AESIs)
percentage of participantsObinutuzumab + Bendamustine
Percentage of Participants With AEs of Special Interest (AESIs)45.8
SecondaryPercentage of Participants With Infusion-related Reactions (IRRs)

IRRs were defined as AEs occurring during or within 24 hours following the administration of an infusion and considered related to drug treatment.

Time frame:
Up to end of treatment at 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Infusion-related Reactions (IRRs)
percentage of participantsObinutuzumab + Bendamustine
Percentage of Participants With Infusion-related Reactions (IRRs)20.8
SecondaryPercentage of Participants Who Discontinued Treatment Prematurely
Time frame:
Up to end of treatment at 6 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Treatment Prematurely
percentage of participantsObinutuzumab + Bendamustine
Percentage of Participants Who Discontinued Treatment Prematurely41.7
SecondaryPercentage of Participants With Previous/Concomitant Diseases
Time frame:
Up to approximately 4.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Previous/Concomitant Diseases
percentage of participantsObinutuzumab + Bendamustine
Percentage of Participants With Previous/Concomitant Diseases97.2
SecondaryPercentage of Participants With Concomitant Medication

Concomitant therapies included any medication (prescription medication, over-the-counter medications, herbal/homeopathic remedies, nutritional supplements) used by subjects in the 7 days prior to screening until the end of treatment. The following treatments were not permitted during the study treatment period: investigational or unauthorized or unapproved medicinal products, immunotherapy or radioimmunotherapy (other than the trial immunotherapy, obinutuzumab), chemotherapy (other than the trial chemotherapy, bendamustine) and radiotherapy.

Time frame:
From 7 days prior to screening to the end of treatment at 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Concomitant Medication
percentage of participantsObinutuzumab + Bendamustine
Percentage of Participants With Concomitant Medication54.2

Adverse events

Collected over Up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab + Bendamustine25/72 (34.7%)37/72 (51.4%)67/72 (93.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventObinutuzumab + Bendamustine
NeutropeniaBlood and lymphatic system disorders9/72
Febrile neutropeniaBlood and lymphatic system disorders8/72
PyrexiaGeneral disorders8/72
PneumoniaInfections and infestations8/72
Respiratory tract infectionInfections and infestations6/72
Septic shockInfections and infestations3/72
DiarrhoeaGastrointestinal disorders2/72
Infusion related reactionGeneral disorders2/72
Multiple organ dysfunction syndromeGeneral disorders2/72
BronchitisInfections and infestations2/72
Most frequent other events
Showing 10 of 26
Most frequent other events
EventObinutuzumab + Bendamustine
NeutropeniaBlood and lymphatic system disorders48/72
ThrombocytopeniaBlood and lymphatic system disorders30/72
AstheniaGeneral disorders28/72
PyrexiaGeneral disorders27/72
Respiratory tract infectionInfections and infestations19/72
NauseaGastrointestinal disorders17/72
DiarrhoeaGastrointestinal disorders16/72
AnaemiaBlood and lymphatic system disorders14/72
Infusion related reactionGeneral disorders13/72
CoughRespiratory, thoracic and mediastinal disorders11/72

Baseline characteristics

Intent-to-treat (ITT) population included all participants, who received at least one dose of any treatment.

Age, Continuous
Age, Continuous(years)Obinutuzumab + Bendamustine
Median67.9 (42.5 to 83.1)
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab + Bendamustine
Female24
Male48
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Obinutuzumab + Bendamustine
Caucasian71
Indian1
08

Study locations

21 sites
  • Hospital De Txagorritxu; Servicio de Hematologia
    Vitoria, Alava 01009, Spain
  • Hospital General Universitario de Elche; Servicio de Hematologia
    Elche, Alicante 03203, Spain
  • Hospital de Cabueñes; Servicio de Hematología y Hemoterapia
    Gijon, Asturias 33203, Spain
  • Hospital Univ. Central de Asturias; servicio de Hematologia
    Oviedo, Asturias 33011, Spain
  • Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
    Badalona, Barcelona 08915, Spain
  • Hospital Mutua de Terrassa; Servicio de Hematologia
    Terrassa, Barcelona 08221, Spain
  • Hospital de Navarra, Servicio de Hematología
    Pamplona, Navarra 31008, Spain
  • Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Hematologia
    Santa Cruz de Tenerife, Tenerife 38010, Spain
  • Hospital Universitari Vall d'Hebron; Servicio de Hematologia
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
    Barcelona, 08036, Spain
  • Hospital General de Castellon; Servicio de Hematologia
    Castellon, 12004, Spain
  • Hospital Universitario Virgen de las Nieves; Servicio de Hematologia
    Granada, 18014, Spain
  • Hospital de Gran Canaria Dr. Negrin; Servicio de Hematologia
    Las Palmas, 35020, Spain
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital Universitario Puerta de Hierro; Servicio de Hematologia
    Madrid, 28222, Spain
  • Hospital Costa del Sol; Servicio de Hematologia
    Malaga, 29600, Spain
  • Hospital Universitario Virgen Macarena; Servicio de Hematologia
    Sevilla, 41009, Spain
  • Hospital Univ. Nuestra Señora de Valme; Servicio de Hematologia
    Sevilla, 41014, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Hospital Universitario Dr. Peset; Servicio de Hematologia
    Valencia, 46017, Spain
  • Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Nov 2018, 55 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 55 months is close to that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2014
First posted
Feb 25, 2014
StartActual
Apr 9, 2014
Primary completionActual
Nov 19, 2018
CompletionActual
Nov 19, 2018
Results first posted
Nov 26, 2019
Last update
Feb 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02071225
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 25, 2014
Start date
Apr 9, 2014
Primary completion
Nov 19, 2018
Completion
Nov 19, 2018
Results posted
Nov 26, 2019
Last update
Feb 7, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Obinutuzumab

Start the discussion